Company intelligence / Profile preview

TD2 Oncology

Scottsdale, Arizona, United Statestd2inc.com ↗

Ownership: Private
Development stage: Commercial

Overview

TD2 has supported more than 600 biotech and pharma companies in advancing oncology therapies from preclinical research through FDA approval. The company is recognized for its expertise in translational research, regulatory support, advanced flow cytometry, and efficient clinical trial management. It has contributed to numerous first-in-human studies that have led to approvals across various cancer types. As a CRO rather than a therapeutics developer itself, it does not publish its own clinical results.

Therapeutic areas: Oncology
Modalities: Small moleculesTargeted therapiesImmuno-oncology agentsAntibody-drug conjugates (ADCs)Radiopharmaceuticals
Industry: Contract Research Organization

Partnerships

VieCure

Beyond the preview

Go deeper on TD2 Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TD2 Oncology.

Explore the full profile